Aim: To compare gallbladder (GB) emptying in patients with chronic hepatitis C and in those with HCV related cirrhosis.
Method: 20 patients with HCV chronic hepatitis and 20 patients with HCV cirrhosis Child class A were enrolled in the study. The control group included 20 hospitalized patients free of liver disease. We excluded subjects with GB lithiasis or GB anomalies, and those with obesity and diabetes mellitus. In all patients, the following GB variables were measured: fasting volume (FV), minimal residual volume (RV), ejection fraction (EF), wall thickness and area under the emptying curve (AUC). The statistical analysis was performed using the Man-Whitney and Kruskal-Wallis tests and the Pearson correlation coefficient.
Results: In cirrhotic patients, the fasting GB volume (35.62 +/- 4.45cm3) and the residual volume (18.46 +/- 3.27cm3) were larger than in controls: 27.12 +/- 5.38cm3 and 7.28 +/- 3.15cm3, respectively (p < 0.00001). The GB EF was reduced in cirrhotics as compared to controls (p < 0.00001). The patients with HCV chronic hepatitis had a residual volume larger (14.18 +/- 6.11cm3 vs 7.28 +/- 3.15cm3; p = 0.0129), and an EF lower than controls (53.4 +/- 14.15cm3 vs. 72.76 +/- 9.96cm3) (p = 0.0005). The GB emptying curves showed a significantly slower emptying in cirrhotic and chronic hepatitis patients as compared to controls. We found a significant negative correlation in chronic hepatitis patients between EF, on one hand, and overweight and abdominal circumference, on the other. The GB wall was thicker in cirrhotics (5.1 +/- 0.32mm) as compared to controls (2.32 +/- 0.27mm) (p < 0.00001), and also in chronic hepatitis patients as compared to controls (p < 0.0001).
Conclusion: A decrease in GB motility was present both in patients with HCV related cirrhosis and in those with chronic HCV hepatitis. This may be, partly, caused by an increase in GB wall thickness, and might be a risk factor for the development of gallstones.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Gut microbes associated with functional cure of chronic hepatitis B.
Hepatol Int
January 2025
Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo, 162-8640, Japan.
Background And Aims: Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however, the factors contributing to FC remain unclear. We aimed to investigate the gut microbiota profiles of patients with chronic hepatitis B who achieved FC.
View Article and Find Full Text PDFThe Effect of HBV Therapy on Glycemic Control in HBV-Infected Patients With Diabetes: A 90-day Multicenter Study.
J Med Virol
February 2025
Xiangya School of Public Health, Central South University, Changsha, China.
Patients with diabetes are at increased risk of HBV infection; however, the effects of HBV infection and anti-HBV therapy on the management of type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA) remain unclear. From 2016 to 2023, we recruited a multicenter cohort of 355 HBV-infected inpatients, including 136 with T1D, 140 with T2D, and 79 with LADA. The control group included 525 HBV-uninfected inpatients, comparing 171 with T1D, 204 with T2D and 150 with LADA.
View Article and Find Full Text PDFTenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B.
J Med Virol
February 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea.
While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) effectively manage chronic hepatitis B, their long-term effects on lipid metabolism and cardiovascular outcomes remain unclear. This study compares the impact of ETV, TDF, and treatment-naïve (control group) on hyperlipidemia and major adverse cardiac events (MACE) in people living with chronic hepatitis B (PLWHB). We used claim data from the South Korean National Health Insurance Service.
View Article and Find Full Text PDFLong-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy.
J Viral Hepat
February 2025
Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
This study aimed to evaluate the effectiveness of direct-acting antivirals (DAAs) on hepatitis C virus (HCV) hospitalisation trends in Italy, the country with not only the highest burden of HCV-related disease but also the highest number of patients treated for chronic HCV infection in Europe. Incident hospital discharge records in Italy from 2012 to 2019 that included a liver cirrhosis diagnosis without mention of alcohol, hepatocellular carcinoma (HCC), HCV and liver cirrhosis without mention of alcohol and/or HCC, cirrhosis with mention of alcohol, as defined by the International Classification of Diseases (ICD-9-CM) were reviewed. An interrupted time series analysis compared the incidence of cirrhosis and HCC before and after the introduction of DAAs (Year 2015).
View Article and Find Full Text PDFAssociation of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.
J Viral Hepat
February 2025
Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Steatotic liver disease is prevalent among people with hepatitis C virus (HCV). The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasises the metabolic drivers of steatosis and recognises its frequent coexistence with other chronic liver diseases, including HCV. We aimed to evaluate the association of coexisting MASLD and HCV with liver fibrosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!